# Volunteers Taking Cholesterol-Lowering Drugs Needed for Research Study

The Robert Guthrie Biochemical Genetics Laboratory at the Women's and Children's Hospital of Buffalo, Kaleida Health System and University at Buffalo is currently seeking participants for a research study. Participants should be adults who are:

(1) Parents of affected individuals (obligate carriers) or affected individuals with a **lipid storage disease** that is characterized by skeletal muscle symptoms, for example, carnitine palmitoyltransferase (CPT) II deficiency. (VLCAD, LCHAD, MCAD, and carnitine deficiencies will also be included). Note: Participants may or may not have muscle symptoms at the time of entry in the study.

(2) Taking or have taken cholesterol-lowering drugs in the past with or without the presence of muscle symptoms.

Common cholesterol-lowering drugs include Lipitor, Zocor, Pravachol, Crestor, Mevacor, and Leschol. Other lipid-lowering drugs of interest to our study include fibrates, such as Gemfibrozil (Lopid).

The purpose of the study is to determine whether carriers or affected individuals with lipid storage diseases are at increased risk for developing new or more severe muscle symptoms while taking cholesterol-lowering drugs. In preliminary studies, we have observed an increased prevalence of both carriers and affected individuals with certain lipid storage diseases among those who develop muscle symptoms. Approximately 2 teaspoons of blood is needed for the study and a questionnaire will be given to participants for a health history before, during and after drug therapy, as applicable. The principal investigator will reimburse participants for blood drawing fees and shipment costs. The benefits to participants include the provision of risk factor information that may help with future medical care.
For additional information, please call Jeanne Catalano at 716-829-3141 ext. 148 Tuesday/Thursday or by email at jcatalan@buffalo.edu

Note: Grandparents of affected individuals are also encouraged to participate.

The study protocol has been approved by the Health Sciences Institutional Review Board of The University at Buffalo. The Principal Investigator is Dr. Georgirene D. Vladutiu, Professor of Pediatrics, Neurology and Pathology at the School of Medicine and Biomedical Sciences, The University at Buffalo.

For IRB Use

Health Sciences IRB Approval
FROM: 8/26/05 TO: 3/22/06